Imatinib Treatment in Patients with Liver Metastases and Jaundice
Author Information
Author(s): De Pas T, Danesi R, Catania C, Curigliano G, de Braud F
Primary Institution: European Institute of Oncology
Hypothesis
Can imatinib be safely administered to patients with advanced GIST and severe jaundice?
Conclusion
Imatinib can be administered to patients with advanced GIST and severe jaundice without significant toxicity.
Supporting Evidence
- Imatinib was administered at full doses to both patients despite their severe jaundice.
- No significant toxicity was observed during the treatment period.
- Both patients showed stabilization of their disease after resuming imatinib treatment.
Takeaway
Doctors gave a medicine called imatinib to two patients with a type of cancer and yellow skin, and it worked without making them sick.
Methodology
Two patients with advanced GIST and severe jaundice were treated with imatinib and monitored for toxicity and disease progression.
Potential Biases
The small sample size limits the generalizability of the findings.
Limitations
Only two patients were examined, and there was no pharmacokinetic analysis or liver tissue analysis.
Participant Demographics
One male aged 67 and one female aged 42, both with advanced GIST and severe jaundice.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website